United States Biomarker Testing Market: Precision Oncology Growth | Major Companies likes - QIAGEN N.V., Bio-Rad Laboratories, Inc., Illumina, Inc.

Global Biomarker Testing Market is expected to reach growth at a Significant CAGR during the forecast period 2025-2033.

The Biomarker Testing Market, as examined by DataM Intelligence, provides a thorough industry overview enriched with detailed insights, historical data, and essential statistics. The report extensively explores market dynamics and competitive landscapes, featuring profiles of leading companies, their product offerings, pricing strategies, financials, growth plans, and geographic footprint.

Unlock exclusive insights with our detailed sample report (Corporate Email ID to get priority access) @ https://datamintelligence.com/download-sample/biomarker-testing-market-market?ca

Biomarker testing is a diagnostic tool that identifies specific genes, proteins, or molecules in the body to guide disease detection, prognosis, and personalized treatment, particularly in oncology, cardiology, and precision medicine.

Prominent Industry players in the Biomarker Testing Market

The prominent players in Biomarker Testing Market research report are: QIAGEN N.V., Bio-Rad Laboratories, Inc., Illumina, Inc., Labcorp Drug Development, IQVIA, Inc., Quanterix Corporation, Merck KGaA, Abbott Laboratories, Thermo Fisher Scientific Inc., and Q2 Solutions

The companies are primarily focusing on strategies such as new product launches to penetrate the fastest-growing emerging markets across the world.

Buy Now & Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ca

Industry News

September 2025: The FDA granted Breakthrough Therapy Designation (BTD) to olomorasib (in combination with pembrolizumab) for KRAS G12C mutation in NSCLC with high PD-L1 expression, underscoring the increasing clinical importance of this specific biomarker.

September 2025: Exact Sciences launched CancerguardTM, a multi-cancer early detection (MCED) blood test analyzing multiple biomarker classes, marking a major step in the US for non-invasive early cancer screening technology.

August 18, 2025: Cizzle Biotechnology announced a US national rollout and partnership with Omni Health Diagnostics for its proprietary CIZ1B biomarker test to aid in the early detection of lung cancer.

July 2025: The NCCN Colorectal Cancer Guidelines were updated to include circulating tumor DNA (ctDNA) testing by adding Guardant Health's Shield blood test for screening, accelerating the adoption of liquid biopsy for routine cancer care.

July 2025: The FDA approved Sunvozertinib for locally advanced or metastatic EGFR exon 20 insertion mutations in NSCLC, reinforcing the role of companion diagnostics to identify this specific genetic biomarker for targeted therapy.

Speak to Our Senior Analyst and Get Customization in the report as per your requirements @ https://datamintelligence.com/customize/biomarker-testing-market-market?ca

Market Segments

➥ By Test Type: Tumor Testing, Genomic Testing, Molecular Testing, Somatic Testing, Next Generation Sequencing

➥ By Biomarker Type: Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers

➥ By Application: Drug Discovery and Development, Disease Diagnostics, Disease Risk Assessment, Personalized Medicine, Others

➥ By End-User: Hospitals, Clinical Laboratories, Academic and Research Institutes, Others

The Biomarker Testing Market industry is undergoing swift expansion, fueled by breakthroughs in medical technology, growing demand for cutting-edge therapies, and an increasing emphasis on patient-centric care. As the sector advances, in-depth market analysis is essential to track evolving trends, regulatory developments, and new opportunities.

Regions Covered:

The global Biomarker Testing Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa.

☞ North America - US, Canada, Mexico

☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe

☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific

☞ South America- Brazil, Argentina, Colombia, Rest of South America

☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel

FAQs:

✒ What is driving the growth of the Biomarker Testing Market?
✒ Who are the prominent players in the Biomarker Testing Market?
✒ How is the regulatory landscape affecting the Biomarker Testing Market?
✒ What regions are expected to see the highest growth?
✒ What are the key challenges faced by the Biomarker Testing Market?

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights-all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ Technology Road Map Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
✅ Consumer Behavior & Demand Analysis

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.